Apoptosis induction by thalidomide: Critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis?

Current Molecular Pharmacology

Volumn 4, Issue 1, 2011, Pages 26-61

  Knobloch, Jürgen ^a   Jungck, David ^a   Koch, Andrea ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Apoptosis; Bmp Dkk1 Wnt; Fgf Akt; Idiopathic pulmonary fibrosis (IPF); Limb development; Oxidative stress; Teratogen; Thalidomide

Indexed keywords

BETA CATENIN; BONE MORPHOGENETIC PROTEIN; FIBROBLAST GROWTH FACTOR; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; THALIDOMIDE; UBIQUITIN; WNT PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; COUGHING; DNA DAMAGE; FEEDBACK SYSTEM; HUMAN; LIMB BUD; LIMB DEVELOPMENT; LUNG FIBROSIS; MOLECULAR PATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; STEM CELL; TERATOGENICITY;

EID: 78650912364     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211104010026     Document Type: Article

References (244)

1. Allen, B.R. Thalidomide. Br. J. Dermatol. 2001, 144, 227-228.
2. Mellin, G.W.; Katzenstein, M. The saga of thalidomide. Neuropathy to embryopathy; with case reports of congenital anomalies. N. Engl. J. Med. 1962, 267, 1184-1192.
3. Smithells, R.W.; Newman, C.G. Recognition of thalidomide defects. J. Med. Genet. 1992, 29, 716-723.
4. Franks, M.E.; Macpherson, G.R.; Figg, W.D. Thalidomide. Lancet, 2004, 363, 1802-1811.
5. Teo, S.K.; Stirling, D.I.; Zeldis, J.B. Thalidomide as a novel therapeutic agent: new uses for an old product. Drug Discov. Today, 2005, 10, 107-114.
6. Somers, F. Pharmacological properties of thalidomide (alphaphthalimido glutarimide); a new sedative hypnotic drug. Br. J. Pharmacol. Chemother., 1960, 15, 111-116.
7. Lenz, W. Thalidomide and congenital abnormalities. Lancet, 1962, I, 45.
8. McBride, W.G. Thalidomide and congenital abnormalities. Lancet, 1961, 2, 1358.
9. Newman, C.G. Teratogen update: clinical aspects of thalidomide embryopathy--a continuing preoccupation. Teratology, 1985, 32, 133-144.
10. Newman, C.G. The thalidomide syndrome: risks of exposure and spectrum of malformations. Clin. Perinatol., 1986, 13, 555-573.
11. Nowack, E. Die sensible Phase bei der Thalidomid-embryopathie. Humangenetik, 1965, 1, 516-536.
12. Klausner, J.D.; Freedman, V.H.; Kaplan, G. Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use. Clin. Immunol. Immunopathol., 1996, 81, 219-223.
13. Rowland, T.L.; McHugh, S.M.; Deighton, J.; Dearman, R.J.; Ewan, P.W.; Kimber, I. Differential regulation by thalidomide and dex-amethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology, 1998, 40, 11-20.
14. McHugh, S.M.; Rifkin, I.R.; Deighton, J.; Wilson, A.B.; Lachmann, P.J.; Lockwood, C.M.; Ewan, P. W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol., 1995, 99, 160-167.
15. Paravar, T.; Lee, D.J. Thalidomide: mechanisms of action. Int. Rev. Immunol., 2008, 27, 111-135.
16. D'Amato, R.J.; Loughnan, M.S.; Flynn, E.; Folkman, J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA, 1994, 91, 4082-4085.
17. Jurand, A. Early changes in limb buds of chick embryos after thalidomide treatment. J. Embryol. Exp. Morphol., 1966, 16, 289-300.
18. Sauer, H.; Günther, J.; Hescheler, J.; Wartenberg, M. Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals. Am. J. Pathol., 2000, 156, 151-158.
19. Therapontos, C.; Erskine, L.; Gardner, E.R.; Figg, W.D.; Vargesson, N. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci. USA, 2009, 106, 8573-8578.
20. Vargesson, N. Thalidomide-induced limb defects: resolving a 50- year-old puzzle. Bioessays, 2009, 31, 1327-1336.
21. Jakeman, P.; Smith, W.C. Thalidomide in leprosy reaction. Lancet, 1994, 343, 432-433.
22. Schuler-Faccini, L.; Soares, R.C.; de Sousa, A.C.; Maximino, C.; Luna, E.; Schwartz, I.V.; Waldman, C.; Castilla, E.E. New cases of thalidomide embryopathy in Brazil. Birth Defects Res. A Clin. Mol. Teratol., 2007, 79, 671-672.
23. Hansen, J.M.; Harris, C. A novel hypothesis for thalidomide-induced limb teratogenesis: redox misregulation of the NFkappaB pathway. Antioxid. Redox Signal., 2004, 6, 1-14.
24. Stephens, T.D.; Bunde, C.J.; Fillmore, B.J. Mechanism of action in thalidomide teratogenesis. Biochem. Pharmacol., 2000, 59, 1489-1499.
25. Newman, L.M.; Johnson, E.M.; Staples, R.E. Assessment of the effectiveness of animal developmental toxicity testing for human safety. Reprod. Toxicol., 1993, 7, 359-390.
26. Wells, P.G.; Bhuller, Y.; Chen, C.S.; Jeng, W.; Kasapinovic, S.; Kennedy, J.C.; Kim, P. M.; Laposa, R.R.; McCallum, G.P.; Nicol, C.J.; Parman, T.; Wiley, M.J.; Wong, A.W. Molecular and biochemical mechanisms in teratogenesis involving reactive oxygen species. Toxicol. Appl. Pharmacol., 2005, 207, 354-366.
27. Parman, T.; Wiley, M.J.; Wells, P. G. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat. Med., 1999, 5, 582-585.
28. Knobloch, J.; Reimann, K.; Klotz, L.O.; Rüther, U. Thalidomide Resistance Is Based on the Capacity of the Glutathione-Dependent Antioxidant Defense. Mol. Pharm., 2008, 5, 1138-1144.
29. Hansen, J.M.; Gong, S.G.; Philbert, M.; Harris, C. Misregulation of gene expression in the redoxsensitive NF-kappab-dependent limb outgrowth pathway by thalidomide. Dev. Dyn., 2002, 225, 186-194.
30. Hansen, J.M.; Harris, K.K.; Philbert, M.A.; Harris C. Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb. J. Pharmacol. Exp. Ther., 2002, 300, 768-776.
31. Buetler, T.M.; Krauskopf, A.; Ruegg, U.T. Role of superoxide as a signaling molecule. News Physiol. Sci., 2004, 19, 120-123.
32. Kabe, Y.; Ando, K.; Hirao, S.; Yoshida, M.; Handa, H. Redox regulation of NF-kappaB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid. Redox Signal., 2005, 7, 395-403.
33. Fernando, M.R.; Nanri, H.; Yoshitake, S.; Nagata-Kuno, K.; Minakami, S. Thioredoxin regenerates proteins inactivated by oxidative stress in endothelial cells. Eur. J. Biochem., 1992, 209, 917-922.
34. Bergström, R.M.; Erilä, T.; Pirskanen, R. Teratogenic effects of the amino acid leucine in the chicken. Experientia, 1967, 23, 767-768.
35. Debock, C.A.; Peters, A. Effect of thalidomide on the development of the chick embryo. Nature, 1963, 199, 1204-1206.
36. Kemper, F. Thalidomide and development of the chick embryo. Arzneimittelforschung, 1962, 12, 640-641.
37. Knobloch, J.; Shaughnessy, J.D. Jr.; Rüther, U. Thalidomide induces limb deformities by perturbing the Bmp/Dkk1/Wnt signaling pathway. FASEB J., 2007, 21, 1410-1421.
38. Schmahl, H.J.; Dencker, L.; Plum, C.; Chahoud, I.; Nau, H. Stereoselective distribution of the teratogenic thalidomide analogue EM12 in the early embryo of marmoset monkey, Wistar rat and NMRI mouse. Arch. Toxicol., 1996, 70, 749-756.
39. Stephens, T.D. The effect of thalidomide in chicken embryos. Birth Defects Res. Part A Clin. Mol. Teratol., 2009, 85, 725-731.
40. Weicker, H.; Bachmann, K.D.; Pfeiffer, R.A.; Gleiss, J. Thalidomide embryopathy. Dtsch. Med. Wochenschr.1962, 87, 1597-1607.
41. Pérez-Pastén, R.; Martínez-Galero, E.; Garduño-Siciliano, L.; Lara, I.C.; Cevallos, G.C. Effects of dimethylsulphoxide on mice arsenite-induced dysmorphogenesis in embryo culture and cytotoxicity in embryo cells. Toxicol. Lett., 2006, 161, 167-73.
42. Capdevila, J.; Izpisúa Belmonte, J.C. Patterning mechanisms controlling vertebrate limb development. Annu. Rev. Cell Dev. Biol., 2001, 17, 87-132.
43. Martin, G. Making a vertebrate limb: new players enter from the wings. Bioessays, 2001, 23, 865-868.
44. Dudley, A.T.; Ros, M. A.; Tabin, C.J. A re-examination of proximodistal patterning during vertebrate limb development. Nature, 2002, 418, 539-544.
45. Galloway, J.L.; Delgado, I.; Ros, M.A.; Tabin, C.J. A reevaluation of X-irradiation-induced phocomelia and proximodistal limb patterning. Nature, 2009, 460, 400-404.
46. Niswander, L.; Martin, G.R. FGF-4 and BMP-2 have opposite effects on limb growth. Nature, 1993, 361, 68-71.
47. Fallon, J.F.; López, A.; Ros, M. A.; Savage, M.P.; Olwin, B.B.; Simandl, B.K. FGF-2: apical ectodermal ridge growth signal for chick limb development. Science, 1994, 264, 104-107.
48. Niswander, L.; Tickle, C.; Vogel, A.; Booth, I.; Martin, G.R. FGF4 replaces the apical ectodermal ridge and directs outgrowth and patterning of the limb. Cell, 1993, 75, 579-587.
49. Pearse, R.V. 2nd; Tabin, C.J. The molecular ZPA. J. Exp. Zool., 1998, 282, 677-690.
50. Capdevila, J.; Tsukui, T.; Rodríquez Esteban, C.; Zappavigna, V.; Izpisúa Belmonte, J.C. Control of vertebrate limb outgrowth by the proximal factor Meis2 and distal antagonism of BMPs by Gremlin. Mol. Cell, 1999, 4, 839-849.
51. Zúñiga, A.; Haramis, A.P.; McMahon, A.P.; Zeller, R. Signal relay by BMP antagonism controls the SHH/FGF4 feedback loop in vertebrate limb buds. Nature, 1999, 401, 598-602.
52. Hsu, D.R.; Economides, A.N.; Wang, X.; Eimon, P.M.; Harland, R.M. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol. Cell, 1998, 1, 673-683.
53. Gañan, Y.; Macias, D.; Basco, R.D.; Merino, R.; Hurle, J.M. Morphological diversity of the avian foot is related with the pattern of msx gene expression in the developing autopod. Dev. Biol., 1998, 196, 33-41.
54. Pizette, S.; Niswander, L. BMPs negatively regulate structure and function of the limb apical ectodermal ridge. Development, 1999, 126, 883-894.
55. Chiang, C.; Litingtung, Y.; Harris, M.P.; Simandl, B.K.; Li, Y.; Beachy, P.A.; Fallon, J.F. Manifestation of the limb prepattern: limb development in the absence of sonic hedgehog function. Dev. Biol., 2001, 236, 421-435.
56. Khokha, M.K.; Hsu, D.; Brunet, L.J.; Dionne, M.; Harland, R.M. Gremlin is the BMP antagonist required for maintenance of Shh and Fgf signals during limb patterning. Nat. Genet., 2003, 34, 303-307.
57. Tickle, C. Patterning systems--from one end of the limb to the other. Dev. Cell, 2003, 4, 449-458.
58. Logan, C.; Hornbruch, A.; Campbell, I.; Lumsden, A. The role of Engrailed in establishing the dorsoventral axis of the chick limb. Development, 1997, 124, 2317-2324.
59. Tergaonkar, V. NFkappaB pathway: a good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol., 2006, 38, 1647-1653.
60. Bushdid, P.B.; Brantley, D.M.; Yull, F.E.; Blaeuer, G.L.; Hoffman, L.H.; Niswander, L.; Kerr, L.D. Inhibition of NF-kappaB activity results in disruption of the apical ectodermal ridge and aberrant limb morphogenesis. Nature, 1998, 392, 615-618.
61. Kanegae, Y.; Tavares, A.T.; Izpisúa Belmonte, J.C.; Verma, I.M. Role of Rel/NF-kappaB transcription factors during the outgrowth of the vertebrate limb. Nature, 1998, 392, 611-614.
62. Paznekas, W.A.; Cunningham, M.L.; Howard, T.D.; Korf, B.R.; Lipson, M.H.; Grix, A.W.; Feingold, M.; Goldberg, R.; Borochowitz, Z.; Aleck, K.; Mulliken, J.; Yin, M.; Jabs, E.W. Genetic heterogeneity of Saethre-Chotzen syndrome; due to TWIST and FGFR mutations. Am. J. Hum. Genet., 1998, 62, 1370-1380.
63. Rice, D.P.; Aberg, T.; Chan, Y.; Tang, Z.; Kettunen, P.J.; Pakarinen, L.; Maxson, R.E.; Thesleff, I. Integration of FGF and TWIST in calvarial bone and suture development. Development, 2000, 127, 1845-1855.
64. Zuniga, A.; Quillet, R.; Perrin-Schmitt, F.; Zeller, R. Mouse Twist is required for fibroblast growth factormediated epithelialmesenchymal signalling and cell survival during limb morphogenesis. Mech. Dev., 2002, 114, 51-59.
65. Xu, X.; Weinstein, M.; Li, C.; Naski, M.; Cohen, R.I.; Ornitz, D.M.; Leder, P.; Deng, C. Fibroblast growth factor receptor 2 (FGFR2)-mediated reciprocal regulation loop between FGF8 and FGF10 is essential for limb induction. Development, 1998, 125, 753-765.
66. O'Rourke, M.P.; Tam, P.P. Twist functions in mouse development. Int. J. Dev. Biol., 2002, 46, 401-13.
67. Katoh, Y.; Katoh, M. Comparative genomics on FGF7, FGF10, FGF22 orthologs; and identification of fgf25. Int. J. Mol. Med., 2005, 16, 767-770.
68. Cai, J.; Jabs, E.W. A twisted hand: bHLH protein phosphorylation and dimerization regulate limb development. Bioessays, 2005, 27, 1102-1106.
69. Grotewold, L.; Rüther, U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J., 2002, 21, 966-975.
70. Hogan, B.L.M. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev., 1996, 10, 1580-1594.
71. Zuzarte-Luís, V.; Montero, J.A.; Rodriguez-León, J.; Merino, R.; Rodríguez-Rey, J.C.; Hurlé, J.M. A new role for BMP5 during limb development acting through the synergic activation of Smad and MAPK pathways. Dev. Biol., 2004, 272, 39-52.
72. Ahn, K.; Mishina, Y.; Hanks, M.C.; Behringer, R.R.; Crenshaw, E.B. 3rd. BMPR-IA signaling is required for the formation of the apical ectodermal ridge and dorsal-ventral patterning of the limb. Development, 2001, 128, 4449-4461.
73. Maatouk, D.M.; Choi, K.S.; Bouldin, C.M.; Harfe, B.D. In the limb AER Bmp2 and Bmp4 are required for dorsal-ventral patterning and interdigital cell death but not limb outgrowth. Dev. Biol., 2009, 327, 516-523.
74. Niswander, L. Interplay between the molecular signals that control vertebrate limb development. Int. J. Dev. Biol., 2002, 46, 877-881.
75. Robert, B. Bone morphogenetic protein signaling in limb outgrowth and patterning. Dev. Growth Differ., 2007, 49, 455-468.
76. Guha, U.; Gomes, W.A.; Kobayashi, T.; Pestell, R.G.; Kessler, J.A. In vivo evidence that BMP signaling is necessary for apoptosis in the mouse limb. Dev. Biol., 2002, 249, 108-120.
77. Zuzarte-Luís, V.; Hurlé, J.M. Programmed cell death in the developing limb. Int. J. Dev. Biol., 2002, 46, 871-876.
78. Zuzarte-Luis, V.; Hurle, J.M. Programmed cell death in the embryonic vertebrate limb. Semin Cell. Dev. Biol., 2005, 16, 261-269.
79. Guimond, J.C.; Lévesque, M.; Michaud, P.L.; Berdugo, J.; Finnson, K.; Philip, A.; Roy, S. BMP-2 functions independently of SHH signaling and triggers cell condensation and apoptosis in regenerating axolotl limbs. BMC Dev. Biol., 2010, 10, 15.
80. Villacorte, M.; Suzuki, K.; Hayashi, K.; de Sousa Lopes, S.C.; Haraguchi, R.; Taketo, M. M.; Nakagata, N.; Yamada, G. Antagonistic crosstalk of Wnt/beta-catenin/Bmp signaling within the Apical Ectodermal Ridge (AER) regulates interdigit formation. Bio-chem. Biophys. Res. Commun., 2010, 391, 1653-1657.
81. Gañan, Y.; Macias, D.; Duterque-Coquillaud, M.; Ros, M.A.; Hurle, J.M. Role of TGF beta s and BMPs as signals controlling the position of the digits and the areas of interdigital cell death in the developing chick limb autopod. Development, 1996, 122, 2349-2357.
82. Zou, H.; Niswander, L. Requirement for BMP signaling in interdigital apoptosis and scale formation. Science, 1996, 272, 738-741.
83. Macias, D.; Gañan, Y.; Sampath, T.K.; Piedra, M.E.; Ros, M.A.; Hurle, J.M. Role of BMP-2 and OP1(BMP-7) in programmed cell death and skeletogenesis during chick limb development. Development, 1997, 124, 1109-1117.
84. Merino, R.; Rodriguez-Leon, J.; Macias, D.; Gañan, Y.; Economides, A.N.; Hurle, J.M. The BMP antagonist Gremlin regulates outgrowth; chondrogenesis and programmed cell death in the developing limb. Development, 1999, 126, 5515-5522.
85. Michos, O.; Panman, L.; Vintersten, K.; Beier, K.; Zeller, R.; Zuniga, A. Gremlin-mediated BMP antagonism induces the epithelial-mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development, 2004, 131, 3401-3410.
86. Pajni-Underwood, S.; Wilson, C.P.; Elder, C.; Mishina, Y.; Lewandoski, M. BMP signals control limb bud interdigital programmed cell death by regulating FGF signaling. Development, 2007, 134, 2359-2368.
87. Montero, J.A.; Gañan, Y.; Macias, D.; Rodriguez-Leon, J.; Sanz-Ezquerro, J.J.; Merino, R.; Chimal-Monroy, J.; Nieto, M.A.; Hurle, J.M. Role of FGFs in the control of programmed cell death during limb development. Development, 2001, 128, 2075-2084.
88. Lallemand, Y.; Bensoussan, V.; Cloment, C.S.; Robert, B. Msx genes are important apoptosis effectors downstream of the Shh/Gli3 pathway in the limb. Dev. Biol., 2009, 331, 189-198.
89. Yin, Y.; Lin, C.; Ma, L. MSX2 promotes vaginal epithelial differentiation and wolffian duct regression and dampens the vaginal response to diethylstilbestrol. Mol. Endocrinol., 2006, 20, 1535-1546.
90. Gordon, M.D.; Nusse, R. Wnt signaling: multiple pathways; multiple receptors; and multiple transcription factors. J. Biol. Chem., 2006, 281, 22429-22433.
91. Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell. Dev. Biol., 2004, 20, 781-810.
92. Kawakami, Y.; Capdevila, J.; Büscher, D.; Itoh, T.; Rodríguez Esteban, C.; Izpisúa Belmonte, J.C. WNT signals control FGFdependent limb initiation and AER induction in the chick embryo. Cell, 2001, 104, 891-900.
93. Geetha-Loganathan, P.; Nimmagadda, S.; Scaal, M. Wnt signaling in limb organogenesis. Organogenesis, 2008, 4, 109-115.
94. Kengaku, M.; Capdevila, J.; Rodriguez-Esteban, C.; De La Peña, J.; Johnson, R.L.; Izpisúa Belmonte, J. C.; Tabin, C.J. Distinct WNT pathways regulating AER formation and dorsoventral polarity in the chick limb bud. Science, 1998, 280, 1274-1277.
95. Hill, T.P.; Taketo, M.M.; Birchmeier, W.; Hartmann, C. Multiple roles of mesenchymal beta-catenin during murine limb patterning. Development, 2006, 133, 1219-1229.
96. Yu, K.; Ornitz, D.M. FGF signaling regulates mesenchymal differentiation and skeletal patterning along the limb bud proximodistal axis. Development, 2008, 135, 483-491.
97. Chen, S.; Guttridge, D.C.; You, Z.; Zhang, Z.; Fribley, A.; Mayo, M.W.; Kitajewski, J.; Wang, C.Y. Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J. Cell Biol., 2001, 152, 87-96.
98. Mao, B.; Wu, W.; Davidson, G.; Marhold, J.; Li, M.; Mechler, B.M.; Delius, H.; Hoppe, D.; Stannek, P.; Walter, C.; Glinka, A.; Niehrs, C. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature, 2002, 417, 664-667.
99. Lieven, O.; Knobloch, J.; Rüther, U. The regulation of Dkk1 expression during embryonic development. Dev. Biol., 2010, 340, 256-268.
100. Mukhopadhyay, M.; Shtrom, S.; Rodriguez-Esteban, C.; Chen, L.; Tsukui, T.; Gomer, L.; Dorward, D.W.; Glinka, A.; Grinberg, A.; Huang, S.P.; Niehrs, C.; Izpisúa Belmonte, J.C.; Westphal, H. Dickkopf1 is required for embryonic head induction and limb morphogenesis in the mouse. Dev. Cell, 2001, 1, 423-434.
101. Chen, D.; Zhao, M.; Mundy, G.R. Bone morphogenetic proteins. Growth Factors, 2004, 22, 233-241.
102. Zou, H.; Wieser, R.; Massagué, J.; Niswander, L. Distinct roles of type I bone morphogenetic protein receptors in the formation and differentiation of cartilage. Genes Dev., 1997, 11, 2191-2203.
103. Grotewold, L.; Rüther, U. Bmp; Fgf and Wnt signalling in programmed cell death and chondrogenesis during vertebrate limb development: the role of Dickkopf-1. Int. J. Dev. Biol., 2002, 46, 943-947.
104. Wang, J.; Shou, J.; Chen, X. Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene, 2000, 19, 1843-1848.
105. Church, V.L.; Francis-West, P. Wnt signalling during limb development. Int. J. Dev. Biol., 2002, 46, 927-936.
106. Datta, S.; Brunet, R.A.; Greenberg, M.E. Cellular survival: a play in three Akts. Genes Dev., 1999, 13, 2905-2927.
107. Kim, D.; Chung, J. Akt: versatile mediator of cell survival and beyond. J. Biochem. Mol. Biol., 2002, 35, 106-115.
108. Leslie, N.R.; Downes, C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J., 2004, 382, 1-11.
109. Kawakami, Y.; Rodríguez-León, J.; Koth, C.M.; Büscher, D.; Itoh, T.; Raya, A.; Ng, J.K.; Esteban, C.R.; Takahashi, S.; Henrique, D.; Schwarz, M. F.; Asahara, H.; Izpisúa Belmonte, J.C. MKP3 mediates the cellular response to FGF8 signalling in the vertebrate limb. Nat. Cell Biol., 2003, 5, 513-519.
110. Mebratu, Y.; Tesfaigzi, Y. How ERK1/2 activation controls cell proliferation and cell death: Is subcellular localization the answer? Cell Cycle, 2009, 8, 1168-1175.
111. Li, C.; Xu, X.; Nelson, D.K.; Williams, T.; Kuehn, M.R.; Deng, C.X. FGFR1 function at the earliest stages of mouse limb development plays an indispensable role in subsequent autopod morphogenesis. Development, 2005, 132, 4755-4764.
112. Lu, P.; Yu, Y.; Perdue, Y.; Werb, Z. The apical ectodermal ridge is a timer for generating distal limb progenitors. Development, 2008, 135, 1395-1405.
113. Sahni, M.; Ambrosetti, D.C.; Mansukhani, A.; Gertner, R.; Levy, D.; Basilico, C. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev., 1999, 13, 1361-1366.
114. King, M.; Arnold, J. S.; Shanske, A.; Morrow, B.E. T-genes and limb bud development. Am. J. Med. Genet. A, 2006, 140, 1407-1413.
115. Liu, C.; Nakamura, E.; Knezevic, V.; Hunter, S.; Thompson, K.; Mackem, S. A role for the mesenchymal T-box gene Brachyury in AER formation during limb development. Development, 2003, 130, 1327-1337.
116. Singh, M.K.; Petry, M.; Haenig, B.; Lescher, B.; Leitges, M.; Kispert, A. The T-box transcription factor Tbx15 is required for skeletal development. Mech. Dev., 2005, 122, 131-144.
117. Gibson-Brown, J.J.; Agulnik, S.I.; Chapman, D.L.; Alexiou, M.; Garvey, N.; Silver, L.M.; Papaioannou, V.E. Evidence of a role for T-box genes in the evolution of limb morphogenesis and the specification of forelimb/hindlimb identity. Mech. Dev., 1996, 56, 93-101.
118. Rodriguez-Esteban, C.; Tsukui, T.; Yonei, S.; Magallon, J.; Tamura, K.; Izpisua Belmonte, J.C. The Tbox genes Tbx4 and Tbx5 regulate limb outgrowth and identity. Nature, 1999, 398, 814-818.
119. Takeuchi, J.K.; Koshiba-Takeuchi, K.; Matsumoto, K.; Vogel-Höpker, A.; Naitoh-Matsuo, M.; Ogura, K.; Takahashi, N.; Yasuda, K.; Ogura, T. Tbx5 and Tbx4 genes determine the wing/leg identity of limb buds. Nature, 1999, 398, 810-814.
120. Takeuchi, J.K.; Koshiba-Takeuchi, K.; Suzuki, T.; Kamimura, M.; Ogura, K.; Ogura, T. Tbx5 and Tbx4 trigger limb initiation through activation of the Wnt/Fgf signaling cascade. Development, 2003, 130, 2729-39.
121. Minguillon, C.; Del Buono, J.; Logan, M.P. Tbx5 and Tbx4 are not sufficient to determine limb-specific morphologies but have common roles in initiating limb outgrowth. Dev. Cell, 2005, 8, 75-84.
122. Naiche, L.A.; Papaioannou, V.E. Tbx4 is not required for hindlimb identity or post-bud hindlimb outgrowth. Development, 2007, 134, 93-103.
123. Ng, J.K.; Kawakami, Y.; Büscher, D.; Raya, A; Itoh, T.; Koth, C. M.; Rodríguez Esteban, C.; Rodríguez-León, J.; Garrity, D.M.; Fishman, M.C.; Izpisúa Belmonte, J.C. The limb identity gene Tbx5 promotes limb initiation by interacting with Wnt2b and Fgf10. Development, 2002, 129, 5161-5170.
124. Agarwal, P.; Wylie, J.N.; Galceran, J.; Arkhitko, O.; Li, C.; Deng, C.; Grosschedl, R.; Bruneau, B.G. Tbx5 is essential for forelimb bud initiation following patterning of the limb field in the mouse embryo. Development, 2003, 130, 623-633.
125. Rallis, C.; Bruneau, B.G.; Del, Buono. J.; Seidman, C.E.; Seidman, J.G.; Nissim, S.; Tabin, C.J.; Logan, M.P. Tbx5 is required for forelimb bud formation and continued outgrowth. Development, 2003, 130, 2741-2751.
126. Hasson, P.; Del Buono, J.; Logan, M.P. Tbx5 is dispensable for forelimb outgrowth. Development, 2007, 134, 85-92.
127. Koshiba-Takeuchi, K.; Takeuchi, J.K.; Arruda, E.P.; Kathiriya, I.S.; Mo, R.; Hui, C.C.; Srivastava, D.; Bruneau, B.G. Cooperative and antagonistic interactions between Sall4 and Tbx5 pattern the mouse limb and heart. Nat. Genet., 2006, 38, 175-183.
128. Saunders, J.W. Jr. Developmental control of three-dimensional polarity in the avian limb. Ann. N. Y. Acad. Sci., 1972, 193, 29-42
129. Summerbell, D. A quantitative analysis of the effect of excision of the AER from the chick limb-bud. J. Embryol. Exp. Morphol., 1974, 32, 651-660.
130. Zwilling, E. Ectoderm-mesoderm relationship in the development of the chick embryo limb bud. J. Exp. Zool., 1955, 128, 423-441.
131. Wolpert, L.; Tickle, C.; Sampford, M. The effect of cell killing by X-irradiation on pattern formation in the chick limb. J. Embryol. Exp. Morph., 1979, 50, 175-198.
132. Knobloch, J.; Rüther, U. Shedding light on an old mystery: thalidomide suppresses survival pathways to induce limb defects. Cell Cycle, 2008, 7, 1121-1127.
133. Knudson, C.B.; Toole, B.P. Changes in the pericellular matrix during differentiation of limb bud mesoderm. Dev. Biol., 1985, 112, 308-318.
134. Knobloch, J.; Schmitz, I.; Götz, K.; Schulze-Osthoff, K.; Rüther, U. Thalidomide induces limb anomalies by PTEN stabilization; Akt suppression; and stimulation of caspase-dependent cell death. Mol. Cell. Biol., 2008, 28, 529-538.
135. Wells, P.G.; McCallum, G.P.; Chen, C.S.; Henderson, J.T.; Lee, C.J.; Perstin, J.; Preston, T.J.; Wiley, M.J.; Wong, A.W. Oxidative Stress in Developmental Origins of Disease: Teratogenesis; Neurodevelopmental Deficits and Cancer. Toxicol. Sci., 2009, 108, 4-18.
136. Arlen, R.R.; Wells, P.G. Inhibition of thalidomide teratogenicity by acetylsalicylic acid: evidence for prostaglandin H synthasecatalyzed bioactivation of thalidomide to a teratogenic reactive intermediate. J. Pharmacol. Exp. Ther., 1996, 277, 1649-1658.
137. Sies, H. Oxidative stress: introductory remarks. London: Academic Press. 1985, 1-38.
138. Hansen, J.M. Oxidative Stress as a Mechanism of Teratogenesis. Birth Defects Res., 2006, 78, 293-307.
139. Cardey, B.; Enescu, M. Cysteine oxidation by the superoxide radical: a theoretical study. Chemphyschem, 2009, 10, 1642-1648.
140. Parman, T.; Wells P.G. Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice. FASEB J., 2002, 16, 1001-1009.
141. Stavridis, J.C. Oxidation: The Cornerstone of Carcinogenesis: Oxidation and Tobacco Smoke Carcinogenesis. A Relationship Between Cause and Effect. 2007, Springer Verlag GmbH.
142. Dröge, W.; Schulze-Osthoff, K.; Mihm, S.; Galter, D.; Schenk, H.; Eck, H.P.; Roth, S.; Gmünder, H. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J., 1994, 8, 1131-1138.
143. Ortego, M.; Gómez-Hernández, A.; Vidal, C.; Sánchez-Galán, E.; Blanco-Colio, L.M.; Martín-Ventura, J.L.; Tuñón, J.; Diaz, C.; Hernández, G.; Egido, J. HMG-CoA reductase inhibitors reduce I kappa B kinase activity induced by oxidative stress in monocytes and vascular smooth muscle cells. J. Cardiovasc. Pharmacol., 2005, 245, 468-475.
144. Matthews, J.R.; Hay, R.T. Regulation of the DNA binding activity of NF-kappa B. Int. J. Biochem. Cell Biol., 1995, 27, 865-879.
145. Matthews, J.R.; Wakasugi, N.; Virelizier, J.L.; Yodoi, J.; Hay, R.T. Thioredoxin regulates the DNA binding activity of NF-kappa B by reduction of a disulphide bond involving cysteine 62. Nucleic Acids Res., 1992, 20, 3821-3830.
146. Flohé, L.; Brigelius-Flohé, R.; Saliou, C.; Traber, M.G.; Packer, L. Redox regulation of NF-kappa B activation. Free Radic. Biol. Med., 1997, 22, 1115-1126.
147. Rowe, D.A.; Cairns, J.M.; Fallon, J.F. Spatial and temporal patterns of cell death in limb bud mesoderm after apical ectodermal ridge removal. Dev. Biol., 1982, 93, 83-91.
148. Andela, V.B.; Sheu, T.J.; Puzas, E.J.; Schwarz, E.M.; O'Keefe, R.J.; Rosier, R.N. Malignant reversion of a human osteosarcoma cell line; Saos-2; by inhibition of NFkappaB. Biochem. Biophys. Res. Commun., 2002, 297, 237-241.
149. Zimmerman, L. B.; De Jesús-Escobar, J. M.; Harland, R. M. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell, 1996, 86, 599-606.
150. Klein, P.S.; Melton, D.A. A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA, 1996, 93, 8455-8459.
151. Jope, R.S.; Johnson, G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci., 2004, 29, 95-102.
152. Meijer, L.; Skaltsounis, A.L.; Magiatis, P.; Polychronopoulos, P.; Knockaert, M.; Leost, M.; Ryan, X.P.; Vonica, C.A.; Brivanlou, A.; Dajani, R.; Crovace, C.; Tarricone, C.; Musacchio, A.; Roe, S.M.; Pearl, L.; Greengard, P. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem. Biol., 2003, 10, 1255-1266.
153. Lee, Y.H.; White, M.F. Insulin receptor substrate proteins and diabetes. Arch. Pharm. Res., 2004, 27, 361-370.
154. Waite, K.A.; and Eng, C. BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels. Hum. Mol. Genet., 2003, 12, 679-684.
155. Beurel, E.; Jope, R.S. The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog. Neurobiol., 2006, 79, 173-189.
156. Huang, Z.; Wang, R.; Xie, H.; Shang, W.; Manicassamy, S.; Sun, Z. Stabilized -catenin potentiates Fasmediated T cell apoptosis. J. Immunol., 2008, 180, 6586-6592.
157. Brunet, A.; Bonni, A.; Zigmond, M.J.; Lin, M.Z.; Juo, P.; Hu, L.S.; Anderson, M.J.; Arden, K.C.; Blenis, J.; Greenberg, M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 1999, 96, 857-868.
158. Suhara, T.; Kim, H.S.; Kirshenbaum, L.A.; Walsh, K. Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. Mol. Cell. Biol., 2002, 22, 680-691.
159. Böhm, J.; Sustmann, C.; Wilhelm, C.; Kohlhase, J. SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway. Biochem. Biophys. Res. Commun., 2006, 348, 898-907.
160. Kohlhase, J.; Schubert, L.; Liebers, M.; Rauch, A.; Becker, K.; Mohammed, S.N.; Newbury-Ecob, R.; Reardon, W. Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes; including Okihiro syndrome; Holt-Oram syndrome; acro-renal-ocular syndrome; and patients previously reported to represent thalidomide embryopathy. J. Med. Genet., 2003, 40, 473-478.
161. Grotewold, L.; Plum, M.; Dildrop, R.; Peters, T.; Rüther, U. Bambi is coexpressed with Bmp-4 during mouse embryogenesis. Mech. Dev., 2001, 100, 327-330.
162. Simpson, L.; Li, J.; Liaw, D.; Hennessy, I.; Oliner, J.; Christians, F.; Parsons, R. PTEN expression causes feedback upregulation of insulin receptor substrate 2. Mol. Cell. Biol., 2001, 21, 3947-3958.
163. Shao, J.S.; Aly, Z.A.; Lai, C.F.; Cheng, S.L.; Cai, J.; Huang, E.; Behrmann, A.; Towler, D.A. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann. N. Y. Acad. Sci., 2007, 1117, 40-50.
164. Hoogeboom, D.; Burgering, B.M. Should I stay or should I go: beta-catenin decides under stress. Biochim. Biophys. Acta, 2009, 1796, 63-74.
165. Le Bras, M.; Clément, M.V.; Pervaiz, S.; Brenner, C. Reactive oxygen species and the mitochondrial signaling pathway of cell death. Histol. Histopathol., 2005, 20, 205-219.
166. Leslie, N.R.; Batty, I.H.; Maccario, H.; Davidson, L.; Downes, C.P. Understanding PTEN regulation: PIP2; polarity and protein stability. Oncogene, 2008, 27, 5464-5476.
167. Ito, T.; Ando, H.; Suzuki, T.; Ogura, T.; Hotta, K.; Imamura, Y.; Yamaguchi, Y.; Handa, H. Identification of a primary target of thalidomide teratogenicity. Science, 2010, 327, 1345-1350.
168. Goldenberg, S.J.; Marblestone, J.G.; Mattern, M.R.; Nicholson, B. Strategies for the identification of ubiquitin ligase inhibitors. Biochem. Soc. Trans., 2010, 38, 132-136.
169. Brooks, W.S.; Helton, E.S.; Banerjee, S.; Venable, M.; Johnson, L.; Schoeb, T.R.; Kesterson, R.A.; Crawford, D.F. G2E3 is a dual function ubiquitin ligase required for early embryonic development. J. Biol. Chem., 2008, 283, 22304-22315.
170. Vazquez, A.; Bond, E.E.; Levine, A.J.; Bond, G.L. The genetics of the p53 pathway; apoptosis and cancer therapy. Nat. Rev. Drug Discov., 2008, 7, 979-987.
171. Lepper, E.R.; Smith, N.F.; Cox, M.C.; Scripture, C.D.; Figg, W.D. Thalidomide metabolism and hydrolysis: mechanisms and implications. Curr. Drug Metab., 2006, 7, 677-685.
172. Charokopos, N.; Apostolopoulos, N.; Kalapodi, M.; Leotsinidis, M.; Karamanos, N.; Mouzaki, A. Bronchial asthma; chronic obstructive pulmonary disease and NFkappaB. Curr. Med. Chem., 2009, 16, 867-883.
173. Ehrhardt, C.; Ludwig, S. A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell Microbiol., 2009, 11, 863-871.
174. Groneberg, D.A.; Witt, H.; Adcock, I.M.; Hansen, G.; Springer, J. Smads as intracellular mediators of airway inflammation. Exp. Lung Res., 2004, 30, 223-250.
175. Maiese, K.; Li, F.; Chong, Z.Z.; Shang, Y.C. The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol. Ther., 2008, 118, 58-81.
176. Rogliani, P.; Mura, M.; Assunta Porretta, M.; Saltini, C. New perspectives in the treatment of idiopathic pulmonary fibrosis. Ther. Adv. Respir. Dis., 2008, 2, 75-93.
177. Cool, C.D.; Groshong, S.D.; Rai, P.R.; Henson, P.M.; Stewart, J.S.; Brown, K.K. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am. J. Respir. Crit. Care Med., 2006, 174, 654-658.
178. Selman, M.; Thannickal, V.J.; Pardo, A.; Zisman, D. A.; Martinez, F.J.; Lynch, J.P.3rd. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs, 2004, 64, 405-430.
179. Agostini, C.; Siviero, M.; Semenzato, G. Immune effector cells in idiopathic pulmonary fibrosis. Curr. Opin. Pulm. Med., 1997, 3, 348-355.
180. Knobloch, J.; Peters, H.; Jungck, D.; Müller, K.; Strauch, J.; Koch, A. TNFa-induced GM-CSF release from human airway smooth muscle cells depends on activation of an ET-1 autoregulatory positive feedback mechanism. Thorax, 2009, 64, 1044-1052.
181. Ebina, M.; Shimizukawa, M.; Shibata, N.; Kimura, Y.; Suzuki, T.; Endo, M.; Sasano, H.; Kondo, T.; Nukiwa, T. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2004, 169, 1203-1208.
182. Keane, M.P.; Arenberg, D.A.; Lynch, J.P. III; Whyte, R.I.; Iannettoni, M.D.; Burdick, M.D.; Wilke, C.A.; Morris, S.B.; Glass, M.C.; DiGiovine, B.; Kunkel, S.L.; Strieter, R.M. The CXC chemokines; IL-8 and IP10; regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol., 1997, 159, 1437-1443.
183. Tzouvelekis, A.; Anevlavis, S.; Bouros, D. Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir. Res., 2006, 7, 82.
184. Scotton, C.J.; Chambers, R.C. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest, 2007, 132, 1311-1321.
185. Desmoulière, A.; Redard, M.; Darby, I.; Gabbiani, G. Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar. Am. J. Pathol., 1995, 146, 56-66.
186. Garneau-Tsodikova, S.; Thannickal, V.J. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr. Med. Chem., 2008, 15, 2632-2640.
187. Thannickal, V.J.; Horowitz, J.C. Evolving concepts of apoptosis in idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc., 2006, 3, 350-356.
188. Zhang, X.Y.; Zhou, Y.; Liu, W. Q.; Zhao, L.; Li, S.Q. Effects of antisense oligonucleotide to nuclear factor-kappaB on the development of bleomycin-induced pulmonary fibrosis and IL-4 expression therein: experiment with mice. Chinese Med. J., 2007, 87, 195-199.
189. Sen, P.; Chakraborty, P.K.; Raha, S. Tea polyphenol epigallocatechin 3-gallate impedes the anti-apoptotic effects of low-grade repetitive stress through inhibition of Akt and NFkappaB survival pathways. FEBS Lett., 2006, 580, 278-284.
190. Ignotz, R.A.; Massagué, J. Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J. Biol. Chem., 1986, 261, 4337-4345.
191. Postlethwaite, A.E.; Keski-Oja, J.; Moses, H.L.; Kang, A.H. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta. J. Exp. Med., 1987, 165, 251-256.
192. Shannon, J.M.; Hyatt, B.A. Epithelial-mesenchymal interactions in the developing lung. Annu. Rev. Physiol., 2004, 66, 625-645.
193. Koli, K.; Myllärniemi, M.; Vuorinen, K.; Salmenkivi, K.; Ryynänen, M.J.; Kinnula, V.L.; Keski-Oja, J. Bone morphogenetic protein-4 inhibitor gremlin is overexpressed in idiopathic pulmonary fibrosis. Am. J. Pathol., 2006, 169, 61-71.
194. Myllärniemi, M.; Lindholm, P.; Ryynänen, M.J.; Kliment, C.R.; Salmenkivi, K.; Keski-Oja, J.; Kinnula, V.L.; Oury, T.D.; Koli, K. Gremlin-mediated decrease in bone morphogenetic protein signaling promotes pulmonary fibrosis. Am. J. Respir. Crit. Care Med., 2008, 177, 321-329.
195. Xia, H.; Diebold, D.; Nho, R.; Perlman, D.; Kleidon, J.; Kahm, J.; Avdulov, S.; Peterson, M.; Nerva, J.; Bitterman, P.; Henke, C. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J. Exp. Med., 2008, 205, 1659-1672.
196. Vuga, L.J.; Ben-Yehudah, A.; Kovkarova-Naumovski, E.; Oriss, T.; Gibson, K.F.; Feghali-Bostwick, C.; Kaminski, N. WNT5A is a Regulator of Fibroblast Proliferation and Resistance to Apoptosis. Am. J. Respir. Cell Mol. Biol., 2009, 41, 583-589.
197. Zhao, L.; Xiao, K.; Wang, H.; Wang, Z.; Sun, L.; Zhang, F.; Zhang, X.; Tang, F.; He, W. Thalidomide has a therapeutic effect on interstitial lung fibrosis: evidence from in vitro and in vivo studies. Clin. Exp. Immunol., 2009, 157, 310-315.
198. Walters, D.M.; Cho, H.Y.; Kleeberger, S.R. Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2. Antioxid. Redox Signal., 2008, 10, 321-32.
199. Muraoka, R.S.; Bushdid, P.B.; Brantley, D.M.; Yull, F.E.; Kerr, L.D. Mesenchymal expression of nuclear factor-kappaB inhibits epithelial growth and branching in the embryonic chick lung. Dev. Biol., 2000, 225, 322-338.
200. De Langhe, S.P.; Sala, F.G.; Del Moral, P.M.; Fairbanks, T.J.; Yamada, K.M.; Warburton, D.; Burns, R.C.; Bellusci, S. Dickkopf1 (DKK1) reveals that fibronectin is a major target of Wnt signaling in branching morphogenesis of the mouse embryonic lung. Dev. Biol., 2005, 277, 316-331.
201. del Moral, P.M.; De Langhe, S.P.; Sala, F.G.; Veltmaat, J.M.; Tefft, D.; Wang, K.; Warburton, D.; Bellusci, S. Differential role of FGF9 on epithelium and mesenchyme in mouse embryonic lung. Dev. Biol., 2006, 293, 77-89.
202. Gross, T.J.; Hunninghake, G.W. Idiopathic pulmonary fibrosis. N. Engl. J. Med., 2001, 345, 517-525.
203. Kimura, J.; Deutsch, G.H. Key mechanisms of early lung development. Pediatr. Dev. Pathol., 2007, 10, 335-347.
204. Kumar, V.H.; Lakshminrusimha, S.; El Abiad, M.T.; Chess, P.R.; Ryan, R.M. Growth factors in lung development. Adv. Clin. Chem., 2005, 40, 261-316.
205. Eberhart, C.G.; Argani, P. Wnt signaling in human development: beta-catenin nuclear translocation in fetal lung; kidney; placenta; capillaries; adrenal; and cartilage. Pediatr. Dev. Pathol., 2001, 4, 351-357.
206. Pongracz, J.E.; Stockley, R.A. Wnt signalling in lung development and diseases. Respir. Res., 2006, 7, 15.
207. Tebar, M.; Destree, O.; de Vree, W.J.; Ten Have-Opbroek, A. A. Expression of Tcf/Lef and sFrp and localization of beta-catenin in the developing mouse lung. Mech. Dev., 2001, 109, 437-440.
208. Maeda, Y.; Davé, V.; Whitsett, J. A. Transcriptional control of lung morphogenesis. Physiol. Rev., 2007, 87, 219-244.
209. Königshoff, M.; Eickelberg, O. Wnt signaling in lung disease: a failure or a regeneration signal? Am. J. Respir. Cell. Mol. Biol., 2010, 42, 21-31.
210. Zuo, F.; Kaminski, N.; Eugui, E.; Allard, J.; Yakhini, Z.; Ben-Dor, A.; Lollini, L.; Morris, D.; Kim, Y.; DeLustro, B.; Sheppard, D.; Pardo, A.; Selman, M.; Heller, R.A. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA, 2002, 99, 6292-6297.
211. Brabletz, T.; Jung, A.; Dag, S.; Hlubek, F.; Kirchner, T. Betacatenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am. J. Pathol., 1999, 155, 1033-1038.
212. Crawford, H.C.; Fingleton, B.M.; Rudolph-Owen, L.A.; Goss, K.J.; Rubinfeld, B.; Polakis, P.; Matrisian, L.M. The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene, 1999, 18, 2883-2891.
213. Iwano, M.; Plieth, D.; Danoff, T.M.; Xue, C.; Okada, H.; Neilson, E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest., 2002, 110, 341-350.
214. Kim, K.; Lu, Z.; Hay, E.D. Direct evidence for a role of betacatenin/LEF-1 signaling pathway in induction of EMT. Cell Biol. Int., 2002, 26, 463-476.
215. Morali, O.G.; Delmas, V.; Moore, R.; Jeanney, C.; Thiery, J.P.; Larue, L. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene, 2001, 20, 4942-4950.
216. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer, 2002, 2, 442-454.
217. Yang, J.; Liu, Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am. J. Pathol., 2001, 159, 1465-1475.
218. Chilosi, M.; Poletti, V.; Zamò, A.; Lestani, M.; Montagna, L.; Piccoli, P.; Pedron, S.; Bertaso, M.; Scarpa, A.; Murer, B.; Cancellieri, A.; Maestro, R.; Semenzato, G.; Doglioni, C. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am. J. Pathol., 2003, 162, 1495-1502.
219. Königshoff, M.; Balsara, N.; Pfaff, E.M.; Kramer, M.; Chrobak, I.; Seeger, W.; Eickelberg, O. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS ONE, 2008, 3, e2142.
220. Selman, M.; Pardo, A.; Kaminski, N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med., 2008, 5, e62.
221. Königshoff, M.; Kramer, M.; Balsara, N.; Wilhelm, J.; Amarie, O.V.; Jahn, A.; Rose, F.; Fink, L.; Seeger, W.; Schaefer, L.; Günther, A.; Eickelberg, O. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J. Clin. Invest., 2009, 119, 772-787.
222. Cha, S. W.; Tadjuidje, E.; Tao, Q.; Wylie, C.; Heasman, J. Wnt5a and Wnt11 interact in a maternal Dkk1-regulated fashion to activate both canonical and non-canonical signaling in Xenopus axis formation. Development, 2008, 135, 3719-3729.
223. Sen, M.; Ghosh, G. Transcriptional outcome of Wnt-Frizzled signal transduction in inflammation: evolving concepts. J. Immunol., 2008, 181, 4441-4445.
224. Horton, M.R.; Danoff, S. K.; Lechtzin, N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax, 2008, 63, 749.
225. Choe, J.Y.; Jung, H.J.; Park, K.Y.; Kum, Y.S.; Song, G.G.; Hyun, D.S.; Park, S.H.; Kim, S.K. Antifibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm. Res., 2009, Doi: 10.1007/s00011-009-0084-9.
226. Tabata, C.; Tabata, R.; Kadokawa, Y.; Hisamori, S.; Takahashi, M.; Mishima, M.; Nakano, T.; Kubo, H. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J. Immunol., 2007, 179, 708-714.
227. Clifford, R.L.; Deacon, K.; Knox, A. J. Novel regulation of vascular endothelial growth factor-A (VEGFA) by transforming growth factor (beta)1: requirement for Smads; (beta)-catenin; and GSK3(beta). J. Biol. Chem., 2008, 283, 35337-35353.
228. Longo, K.A.; Kennell, J.A.; Ochocinska, M.J.; Ross, S.E.; Wright, W.S.; MacDougald, O.A. Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors. J. Biol. Chem., 2002, 277, 38239-38244.
229. Zerlin, M.; Julius, M.A.; Kitajewski, J. Wnt/Frizzled signaling in angiogenesis. Angiogenesis, 2008, 11, 63-69.
230. Zhang, X.; Gaspard, J.P.; Chung, D.C. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res., 2001, 61, 6050-6054.
231. Rahman, I.; Adcock, I.M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J., 2006, 28, 219-242.
232. Visconti, R.; Grieco, D. New insights on oxidative stress in cancer. Curr. Opin. Drug Discov. Devel., 2009, 12, 240-245.
233. Xia, C.; Meng, Q.; Liu, L.Z.; Rojanasakul, Y.; Wang, X.R.; Jiang, B.H. Reactive Oxygen Species Regulate Angiogenesis and Tumor Growth through Vascular Endothelia. Cancer Res., 2007, 67, 10823-10830.
234. Demedts, M.; Behr, J.; Buhl, R.; Costabel, U.; Dekhuijzen, R.; Jansen, H.M.; MacNee, W.; Thomeer, M.; Wallaert, B.; Laurent, F.; Nicholson, AG.; Verbeken, E. K.; Verschakelen, J.; Flower, C.D.; Capron, F.; Petruzzelli, S.; De Vuyst, P.; van den Bosch, J.M.; Rodriguez-Becerra, E.; Corvasce, G.; Lankhorst, I.; Sardina, M.; Montanari, M.; IFIGENIA Study Group. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med., 2005, 353, 2229-2242.
235. du Bois, R.M. Strategies for treating idiopathic pulmonary fibrosis. Nat. Rev. Drug Discov., 2010, 9, 129-140.
236. Aruoma, O.I.; Halliwell, B.; Hoey, B.M.; Butler, J. The antioxidant action ofN-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic. Biol. Med., 1989, 6, 593-597.
237. Kliment, C.R.; Oury, T.D. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med., 2010, 49, 707-717.
238. Behr, J.; Maier, K.; Degenkolb, B.; Krombach, F.; Vogelmeier, C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am. J. Respir. Crit. Care Med., 1997, 156, 1897-1901.
239. Felton, V.M.; Borok, Z.; Willis, B. C. N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition. Am. J. Physiol. Lung Cell. Mol. Physiol., 2009, 297, L805-812.
240. Waghray, M.; Cui, Z.; Horowitz, J.C.; Subramanian, I.M.; Martinez, F.J.; Toews, G.B.;Thannickal, V.J. Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts. FASEB J., 2005, 19, 854-856.
241. Plasmati, R.; Pastorelli, F.; Cavo, M.; Petracci, E.; Zamagni, E.; Tosi, P.; Cangini, D.; Tacchetti, P.; Salvi, F.; Bartolomei, I.; Michelucci, R.; Tassinari, C.A. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology, 2007, 69, 573-581.
242. Armoiry, X.; Aulagner, G.; Facon, T. Lenalidomide in the treatment of multiple myeloma: a review. J. Clin. Pharm. Ther., 2008, 33, 219-226.
243. Castaneda, C.P.; Zeldis, J.B.; Freeman, J.; Quigley, C.; Brandenburg, N.A.; Bwire, R. RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide. Drug Saf., 2008, 31, 743-752.
244. Adair-Kirk, T.L.; Senior, R.M. Fragments of extracellular matrix as mediators of inflammation. Int. J. Biochem. Cell. Biol., 2008, 40, 1101-1010.